Revisão das orientações metodológicas de estudos de avaliação económica de medicamentos em Portugal

Pereira, João

doi:10.1159/000495740

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This timeframe was chosen due to the rapid evolution of the technologies being evaluated, the limited data available, and the fact that the health system is not yet fully organized to use genomic panel data extensively. A discount rate of 4 percent was applied when calculating the present value of each group of costs, as suggested by the Portuguese official economic evaluation guidelines (31). The protocol used for cost modeling, together with the choice of the statistical distributions and the definition of the output functions, is available in Supplementary Material 2.…”

Section: Overview Of the Multimethodologymentioning

confidence: 99%

Advancing hospital-based health technology assessment: evaluating genomic panel contracting strategies for blood tumors through a multimethodology

Afonso,

Vieira,

Pereira

et al. 2023

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Introduction The adoption of genomic technologies in the context of hospital-based health technology assessment presents multiple practical and organizational challenges. Objective This study aimed to assist the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa) decision makers in analyzing which acute myeloid leukemia (AML) genomic panel contracting strategies had the highest value-for-money. Methods A tailored, three-step approach was developed, which included: mapping clinical pathways of AML patients, building a multicriteria value model using the MACBETH approach to evaluate each genomic testing contracting strategy, and estimating the cost of each strategy through Monte Carlo simulation modeling. The value-for-money of three contracting strategies – “Standard of care (S1),” “FoundationOne Heme test (S2),” and “New diagnostic test infrastructure (S3)” – was then analyzed through strategy landscape and value-for-money graphs. Results Implementing a larger gene panel (S2) and investing in a new diagnostic test infrastructure (S3) were shown to generate extra value, but also to entail extra costs in comparison with the standard of care, with the extra value being explained by making available additional genetic information that enables more personalized treatment and patient monitoring (S2 and S3), access to a broader range of clinical trials (S2), and more complete databases to potentiate research (S3). Conclusion The proposed multimethodology provided IPO Lisboa decision makers with comprehensive and insightful information regarding each strategy’s value-for-money, enabling an informed discussion on whether to move from the current Strategy S1 to other competing strategies.

show abstract

Section: Overview Of the Multimethodologymentioning

confidence: 99%

Advancing hospital-based health technology assessment: evaluating genomic panel contracting strategies for blood tumors through a multimethodology

Afonso,

Vieira,

Pereira

et al. 2023

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

“…En el estudio NEPTUNO, los pacientes del grupo de polipíldora cardiovascular también mostraron un menor uso de recursos en comparación con las otras cohortes [357][358][359] . Las pérdidas de productividad también fueron menores en los pacientes que recibieron la polipíldora cardiovascular en comparación con las otras cohortes, no solo en cuanto al número de pacientes que no tuvieron reinserción laboral (11.5% vs. 14.7% en grupo de monocomponentes, 15.2% en grupo de equipotentes y 15.6% en grupo de otras terapias; p < 0.003), sino también en cuanto al número de días no trabajados por enfermedad durante el periodo de seguimiento (6.4 días vs. 8.4 días en grupo de monocomponentes, 8.3 días en grupo de equipotentes y 7.9 días en grupo de otras terapias; p < 0.001).…”

Section: Sección 2 Evidencias De Costoefectividad De La Estrategia Co...unclassified

Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo

Ponte-Negretti,

Zaidel,

López-Santi

et al. 2024

ACM

View full text Add to dashboard Cite

“…These guidelines were defined with pharmaceutical products in mind. However, evolution of HTA methodologies, international collaborations, and opportunities to incorporate real-world evidence along the product life cycle raised additional methodological challenges [9]. Recently, the Portuguese Commission for Health Technology Assessment (CATS) updated the Portuguese guidelines on economic evaluation, making various changes to the HTA methodology [10].…”

Section: Introductionmentioning

confidence: 99%

HTA Reshaping: Rethinking the Health Technology Assessment Framework in Portugal

Pereira

Alves

Rodrigues³

et al. 2021

Port J Public Health

View full text Add to dashboard Cite

Introduction: Health technology assessment (HTA) aims to provide decision makers with relevant data to make informed choices. Recent changes in the Portuguese HTA framework have altered substantially the assessment methodology with regard to economic evaluation, with potential impacts on access and process efficiency. The HTA Reshaping Project had as its main objective informing the debate on HTA in Portugal, thereby identifying improvement opportunities and solutions to the HTA framework that address future challenges. Methods: The project comprised several phases, i.e., (1) mapping and evaluation of different HTA frameworks across Europe, identifying best practices and key variables to consider in future frameworks; (2) conduction of in-depth interviews with relevant stakeholders (n = 11); and (3) development of 2 workshops – one with young professionals (n = 12) and another with relevant HTA stakeholders (n = 19) – to consolidate and further explore vital elements of HTA, aimed at brainstorming ideas and developing solutions to improve some of the most critical points, with a view to addressing future challenges. Results: The comparison of HTA frameworks showed that their purpose and sophistication vary across European countries. For example, the need for economic evidence is not unanimous, and reimbursement agreements vary considerably. Among the stakeholders interviewed there was a high level of agreement on priorities that should be addressed, e.g., expanding and creating national level registries and assuring patient participation throughout the HTA process. The possibility of using managed entry agreements to enhance patients’ access, applying multi-indication pricing for medicines with different therapeutic values per indication, and improvement of registry/system interoperability gathered a moderate level of agreement. Conclusions: The Portuguese HTA framework might be further adapted to upcoming challenges and should evolve to improve access to innovative therapies. There is still a long path towards the convergence of HTA frameworks in EU member states.

show abstract

Revisão das orientações metodológicas de estudos de avaliação económica de medicamentos em Portugal

Cited by 3 publications

References 23 publications

Advancing hospital-based health technology assessment: evaluating genomic panel contracting strategies for blood tumors through a multimethodology

Advancing hospital-based health technology assessment: evaluating genomic panel contracting strategies for blood tumors through a multimethodology

Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo

HTA Reshaping: Rethinking the Health Technology Assessment Framework in Portugal

Contact Info

Product

Resources

About